186 related articles for article (PubMed ID: 21971513)
1. Targeting JAK3 in kidney transplantation: current status and future options.
Wojciechowski D; Vincenti F
Curr Opin Organ Transplant; 2011 Dec; 16(6):614-9. PubMed ID: 21971513
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib in kidney transplantation.
Wojciechowski D; Vincenti F
Expert Opin Investig Drugs; 2013 Sep; 22(9):1193-9. PubMed ID: 23841583
[TBL] [Abstract][Full Text] [Related]
3. Targeting JAK/STAT Signaling to Prevent Rejection After Kidney Transplantation: A Reappraisal.
Baan CC; Kannegieter NM; Felipe CR; Tedesco Silva H
Transplantation; 2016 Sep; 100(9):1833-9. PubMed ID: 27163538
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib Halts Progression of Graft Dysfunction in a Rat Model of Mixed Cellular and Humoral Rejection.
Rovira J; Ramírez-Bajo MJ; Banon-Maneus E; Lazo-Rodríguez M; Moya-Rull D; Hierro-Garcia N; Tubita V; Piñeiro GJ; Revuelta I; Ventura-Aguiar P; Cucchiari D; Oppenheimer F; Brunet M; Campistol JM; Diekmann F
Transplantation; 2018 Jul; 102(7):1075-1084. PubMed ID: 29620612
[TBL] [Abstract][Full Text] [Related]
5. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders.
West K
Curr Opin Investig Drugs; 2009 May; 10(5):491-504. PubMed ID: 19431082
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinab in renal transplantation.
Zand MS
Transplant Rev (Orlando); 2013 Jul; 27(3):85-9. PubMed ID: 23849222
[TBL] [Abstract][Full Text] [Related]
7. Treating inflammation with the Janus kinase inhibitor CP-690,550.
Vijayakrishnan L; Venkataramanan R; Gulati P
Trends Pharmacol Sci; 2011 Jan; 32(1):25-34. PubMed ID: 21144599
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates.
Borie DC; Changelian PS; Larson MJ; Si MS; Paniagua R; Higgins JP; Holm B; Campbell A; Lau M; Zhang S; Flores MG; Rousvoal G; Hawkins J; Ball DA; Kudlacz EM; Brissette WH; Elliott EA; Reitz BA; Morris RE
Transplantation; 2005 Apr; 79(7):791-801. PubMed ID: 15818321
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.
Vafadari R; Quaedackers ME; Kho MM; Mol WM; Chan G; Weimar W; Baan CC
Transplantation; 2012 Sep; 94(5):465-72. PubMed ID: 22960764
[TBL] [Abstract][Full Text] [Related]
10. Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis.
Di Lernia V; Bardazzi F
Drug Des Devel Ther; 2016; 10():533-9. PubMed ID: 26889081
[TBL] [Abstract][Full Text] [Related]
11. Janus kinase inhibition for immunosuppression in solid organ transplantation: Is there a role in complex immunologic challenges?
Moore CA; Iasella CJ; Venkataramanan R; Lakkis FG; Smith RB; McDyer JF; Zeevi A; Ensor CR
Hum Immunol; 2017 Feb; 78(2):64-71. PubMed ID: 27998802
[TBL] [Abstract][Full Text] [Related]
12. An Update on Calcineurin Inhibitor-Free Regimens: The Need Persists, but the Landscape has Changed.
Webber AB; Vincenti F
Transplantation; 2016 Apr; 100(4):836-43. PubMed ID: 27003097
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
Gupta AK; Cernea M; Lynde CW
Skin Therapy Lett; 2017 Mar; 22(2):1-7. PubMed ID: 28329404
[TBL] [Abstract][Full Text] [Related]
14. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
Tanaka Y; Yamaoka K
Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib.
Adis Editorial
Drugs R D; 2010; 10(4):271-84. PubMed ID: 21171673
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.
Vincenti F; Tedesco Silva H; Busque S; O'Connell P; Friedewald J; Cibrik D; Budde K; Yoshida A; Cohney S; Weimar W; Kim YS; Lawendy N; Lan SP; Kudlacz E; Krishnaswami S; Chan G
Am J Transplant; 2012 Sep; 12(9):2446-56. PubMed ID: 22682022
[TBL] [Abstract][Full Text] [Related]
17. Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates.
Borie DC; Larson MJ; Flores MG; Campbell A; Rousvoal G; Zhang S; Higgins JP; Ball DJ; Kudlacz EM; Brissette WH; Elliott EA; Reitz BA; Changelian PS
Transplantation; 2005 Dec; 80(12):1756-64. PubMed ID: 16378072
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib for treatment of rheumatoid arthritis.
Rakieh C; Conaghan PG
Adv Ther; 2013 Aug; 30(8):713-26. PubMed ID: 23943546
[TBL] [Abstract][Full Text] [Related]
19. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants.
Borie DC; O'Shea JJ; Changelian PS
Trends Mol Med; 2004 Nov; 10(11):532-41. PubMed ID: 15519279
[TBL] [Abstract][Full Text] [Related]
20. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
Mamolo C; Harness J; Tan H; Menter A
J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):192-203. PubMed ID: 23294276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
